Jan Lenaerts

1.4k total citations
36 papers, 622 citations indexed

About

Jan Lenaerts is a scholar working on Rheumatology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Jan Lenaerts has authored 36 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Rheumatology, 14 papers in Pathology and Forensic Medicine and 13 papers in Immunology. Recurrent topics in Jan Lenaerts's work include Rheumatoid Arthritis Research and Therapies (14 papers), Systemic Sclerosis and Related Diseases (13 papers) and Spondyloarthritis Studies and Treatments (11 papers). Jan Lenaerts is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (14 papers), Systemic Sclerosis and Related Diseases (13 papers) and Spondyloarthritis Studies and Treatments (11 papers). Jan Lenaerts collaborates with scholars based in Belgium, United States and Netherlands. Jan Lenaerts's co-authors include Ellen De Langhe, Nathan Vastesaeger, Joachim Sieper, J. Wollenhaupt, L. Myasoutova, Yeong Wook Song, Mazurov Vi, D. K. Chitkara, Martín Rudwaleit and René Westhovens and has published in prestigious journals such as PLoS ONE, The Journal of Clinical Endocrinology & Metabolism and CHEST Journal.

In The Last Decade

Jan Lenaerts

34 papers receiving 606 citations

Peers

Countries citing papers authored by Jan Lenaerts

Since Specialization

Citations

This map shows the geographic impact of Jan Lenaerts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Lenaerts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Lenaerts more than expected).

Fields of papers citing papers by Jan Lenaerts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Lenaerts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Lenaerts. The network helps show where Jan Lenaerts may publish in the future.

Co-authorship network of co-authors of Jan Lenaerts

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Lenaerts. A scholar is included among the top collaborators of Jan Lenaerts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Lenaerts. Jan Lenaerts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Autoantibodies against the NineTeen complex and U5 RNP in systemic sclerosis 2023 ·Journal of Autoimmunity ·Jean‐Baptiste Vulsteke, Vanessa Smith, Carolien Bonroy, Jan Lenaerts, Rita Derua, Wim Wuyts, Daniël Blockmans, Petra De Haes, Yves Piette, Ellen De Langhe, Xavier Bossuyt	1
2	Identification of new telomere- and telomerase-associated autoantigens in systemic sclerosis 2023 ·Journal of Autoimmunity ·Jean‐Baptiste Vulsteke, Vanessa Smith, Carolien Bonroy, Rita Derua, Daniël Blockmans, Petra De Haes, Steven Vanderschueren, Jan Lenaerts, Kristl G. Claeys, Wim Wuyts, Patrick Verschueren, (unknown), Yves Piette, Ellen De Langhe, Xavier Bossuyt	11
3	AB0421 REAL-WORLD EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS 2023 ·Annals of the Rheumatic Diseases ·(unknown), Patrick Durez, Jan Lenaerts, (unknown), Patrick Verschueren	3
4	Anti-RuvBL1/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern 2022 ·Annals of the Rheumatic Diseases ·Jean‐Baptiste Vulsteke, Yves Piette, Carolien Bonroy, Patrick Verschueren, Daniël Blockmans, Steven Vanderschueren, Kristl G. Claeys, Petra De Haes, Jan Lenaerts, Wim Wuyts, Takashi Matsushita, Vanessa Smith, Ellen De Langhe, Xavier Bossuyt	10
5	Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis 2021 ·Lara D. Veeken ·Ann‐Sophie De Craemer, Thomas Renson, (unknown), Liesbet Van Praet, Heleen Cypers, Gaëlle Varkas, Rik Joos, (unknown), Lieve Gyselbrecht, Isabelle Peene, Kristof Thevissen, Félicie Costantino, Maria Antonietta D’Agostino, Jan Lenaerts, Philippe Carron, Filip Van den Bosch, Dirk Elewaut	19
6	A mixed method study exploring patient satisfaction and feasibility of two exercise programmes in systemic sclerosis-associated microstomia 2021 ·Rheumatology Advances in Practice ·(unknown), Kristien Van der Elst, Patrick Verschueren, Jan Lenaerts, René Westhovens, Ellen De Langhe	3
7	The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review 2019 ·Clinical Rheumatology ·(unknown), (unknown), Jean‐Baptiste Vulsteke, Jan Lenaerts, Ellen De Langhe	13
8	Diagnostic Ability of a Dynamic Multidisciplinary Discussion in Interstitial Lung Diseases 2018 ·CHEST Journal ·Laurens De Sadeleer, (unknown), Jonas Yserbyt, Hans Slabbynck, Johny Verschakelen, Eric Verbeken, Birgit Weynand, Ellen De Langhe, Jan Lenaerts, Benoît Nemery, Dirk Van Raemdonck, Geert M. Verleden, Athol U. Wells, Wim Wuyts	70
9	High prevalence of occupational exposure to solvents or silica in male systemic sclerosis patients: a Belgian cohort analysis 2018 ·Clinical Rheumatology ·(unknown), Marie Vanthuyne, Daniël Blockmans, Frédéric Houssiau, Jan Lenaerts, René Westhovens, Benoît Nemery, Ellen De Langhe	27
10	AB1401-HPR An exploratory study evaluating feasibility and effectiveness of two different exercise programs in systemic sclerosis associated microstomia 2018 ·Annals of the Rheumatic Diseases ·(unknown), (unknown), (unknown), René Westhovens, Jan Lenaerts, Ellen De Langhe	2
11	A Nationwide Survey on Patient’s versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study 2016 ·PLoS ONE ·Sophie De Mits, Jan Lenaerts, Bert Vander Cruyssen, Herman Mielants, René Westhovens, Patrick Durez, Dirk Elewaut, (unknown)	17
12	The isotype repertoire of antibodies against novel UH-RA peptides in rheumatoid arthritis 2016 ·Arthritis Research & Therapy ·(unknown), Piet Geusens, Jan Lenaerts, J. Vanhoof, Piet Stinissen, Veerle Somers	1
13	Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics 2016 ·Lara D. Veeken ·Joachim Sieper, Martín Rudwaleit, Jan Lenaerts, J. Wollenhaupt, L. Myasoutova, Sung‐Hwan Park, Yeong Wook Song, Ruji Yao, Susan Huyck, (unknown), Denesh K. Chitkara, Nathan Vastesaeger	14
14	Autoantibodies to two novel peptides in seronegative and early rheumatoid arthritis 2016 ·Lara D. Veeken ·(unknown), (unknown), H.W. van Steenbergen, Piet Geusens, Jan Lenaerts, Klaartje Somers, Piet Stinissen, Annette H M van der Helm–van Mil, Veerle Somers	21
15	Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis : A Randomized, Double-Blind, Placebo-Controlled Trial At 24 Weeks 2013 ·Data Archiving and Networked Services (DANS) ·Maxime Dougados, D. van der Heijde, J. Sieper, (unknown), Walter P. Maksymowych, Gustavo Citera, Junxiang Wei, Jan Lenaerts, Ronald Pedersen, R. Bonin, Ehab Mahgoub, Bonnie Vlahos, (unknown)	3
16	Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 2013 ·Annals of the Rheumatic Diseases ·Joachim Sieper, Jan Lenaerts, J. Wollenhaupt, Martín Rudwaleit, Mazurov Vi, L. Myasoutova, (unknown), Yeong Wook Song, (unknown), D. K. Chitkara, Nathan Vastesaeger	147
17	Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2 2013 ·Annals of the Rheumatic Diseases ·Joachim Sieper, Jan Lenaerts, J. Wollenhaupt, Martín Rudwaleit, Mazurov Vi, L. Myasoutova, (unknown), Yeong Wook Song, (unknown), D. K. Chitkara, Nathan Vastesaeger	42
18	A nationwide survey on patient's versus physician's evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: the Be-Raise study 2011 ·Ghent University Academic Bibliography (Ghent University) ·Jan Lenaerts, Bert Vander Cruyssen, Herman Mielants, René Westhovens, Patrick Durez, Dirk Elewaut	1
19	Belgian patients with familial and sporadic ankylosing spondylitis differ in disease phenotype 2006 ·Ghent University Academic Bibliography (Ghent University) ·Kurt De Vlam, Nathan Vastesaeger, (unknown), Annelies Boonen, Jan Lenaerts, Emmanuel Lesaffre, Herman Mielants, Serge Steinfeld, Clio Ribbens, (unknown), L Dewulf	2
20	Musculoskeletal Effects of the Recombinant Human IGF-I/IGF Binding Protein-3 Complex in Osteoporotic Patients with Proximal Femoral Fracture: A Double-Blind, Placebo-Controlled Pilot Study 2002 ·The Journal of Clinical Endocrinology & Metabolism ·Steven Boonen, Clifford J. Rosen, Roger Bouillon, Andreas Sommer, M J McKay, David Rosen, Steven P. Adams, Paul Broos, Jan Lenaerts, J. Raus, Dirk Vanderschueren, Piet Geusens	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact